Red cell distribution width as a prognostic predictor for colorectal cancer: a meta-analysis.

Clin Transl OncolApr 13, 2026 (epub)
Clinical ResearchOncology (Medical)GastroenterologyOpen access

Ruixue Fan, Yijiang Zhang, Junwei Feng

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis assessed whether preoperative red cell distribution width (RDW) predicts postoperative survival in people with colorectal cancer (CRC). It included 16 studies involving 20,500 individuals. Elevated RDW-CV was associated with poorer overall survival (multivariable-adjusted HR = 1.27, 95% CI 1.00-1.60) and disease-free survival (HR = 1.16, 95% CI 1.01-1.33). RDW-SD showed a stronger association with overall survival (HR = 1.89, 95% CI 1.31-2.72). The authors conclude that higher preoperative RDW is linked to adverse postoperative outcomes, while noting that the evidence is predominantly retrospective.

Key findings

  • Elevated preoperative RDW-CV was associated with poorer overall survival (HR = 1.27, 95% CI 1.00-1.60; I 2 = 68%).
  • RDW-SD had a stronger association with overall survival (HR = 1.89, 95% CI 1.31-2.72).
  • High preoperative RDW-CV was associated with inferior disease-free survival (HR = 1.16, 95% CI 1.01-1.33; I 2 = 54%).
  • Among patients who did not receive neoadjuvant therapy, RDW was associated with overall survival (HR = 1.64, 95% CI 1.15-2.34).

Why it matters

RDW is an accessible blood-test measure, and its association with postoperative survival suggests it may contribute to risk assessment in CRC. The findings also indicate that RDW-CV and RDW-SD may differ in prognostic performance. However, these associations do not establish that RDW itself causes poorer outcomes or that using it to guide care improves survival.

What to keep in mind

The evidence was predominantly retrospective, and standardized RDW thresholds and measurement timing were lacking. Heterogeneity was reported for the RDW-CV survival analyses.

Source

Published in Clin Transl Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.